Company Milestones

Our Beginning

Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history.

1991

First Gene Discovery

Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma.

1993

BRCA1 Discovery

Myriad scientists publish in Science the discovery of the BRCA1 gene that is associated with hereditary breast and ovarian cancer.

1994

Public Company

Myriad becomes a public company and is traded on NASDAQ under the ticker: MYGN.

1995

BRCA2 Discovery

Myriad announces the discovery of the BRCA2 gene that is associated with hereditary breast and ovarian cancer.

1995

BRACAnalysis® Launches

Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market.

1996

PTEN Discovery

Myriad announces the discovery of the PTEN gene that is associated with a large number of cancers.

1997

ProNet Launches

Myriad launches ProNet, a proprietary protein-interaction technology.

1998

Myriad Pharmaceuticals

Myriad incorporates Myriad Pharmaceuticals to develop novel therapies.

1999

COLARIS® Launches

Myriad launches COLARIS®, a genetic test for hereditary colorectal and uterine cancer.

2000

Rice genome map

Myriad announces complete map of the rice genome.

2001

MELARIS® Launches

Myriad launches MELARIS®, a test for melanoma. Myriad publishes in Cell, the discovery of a novel HIV cellular process.

2001

COLARIS AP® Launches

Myriad launches COLARIS AP®, a genetic test for FAP colon cancer syndrome.

2002

DEP1 Discovery

Myriad announces the discovery of major depression gene DEP1 in collaboration with Abbott Laboratories.

2003

Myriad submits investigational new drug applications

Myriad submits investigational new drug applications on two cancer drugs to FDA.

2004

100,000 tests

Myriad tests 100,000 women for breast cancer predisposition.

2004

Clinical Trial for Phase 2 Alzheimer's drug

Myriad announces results of a Phase 2 Alzheimer’s drug clinical trial.

2005

BART Launches

Myriad launches BART, a large rearrangement test for high-risk patients with breast cancer.

2006

Phase 2 clinical trial for Azixa

Myriad announces third Phase 2 clinical trial for Azixa, a molecular disruption agent.

2007

Preventative BRACAnalysis® Launches

Myriad launches BRACAnalysis® for the women’s health preventative care market, significantly expanding access to genetic cancer testing.

2008

Prolaris® Launches

Myriad launched Prolaris®, the first ever prognostic test to predict prostate cancer survival and help guide treatment decisions.

2010

PARP Companion Diagnostics

Myriad enters into three companion diagnostic collaborations for PARP inhibitors used in patients with ovarian cancer.

2011

One-Million Milestone

The one-millionth patient is tested with BRACAnalysis® test.

2013

BRACAnalysis CDx® Receives FDA Approval

Myriad receives FDA approval for its BRACAnalysis CDx® test to identify patients with ovarian cancer who may benefit from the PARP inhibitor Lynparza (olaparib).

2014

Expansion into Mental Health

Myriad acquires Assurex Health and the GeneSight® genetic test for several mental health conditions.

2016

EndoPredict® Launches

EndoPredict® test is launched in the United States, providing three separate results to optimize treatment for patients with breast cancer.

2017

RiskScore® Launches

Myriad launches RiskScore® test, providing women with a comprehensive, personalized breast cancer risk assessment.

2017

BRACAnalysis CDx® Companion Diagnostic

Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for Lynparza in patients with metastatic breast cancer.

2018

Expansion into Reproductive Health

Myriad acquires Counsyl and enters the reproductive genetic testing market.

2018

RiskScore® Validation in Additional Ancestries

Myriad validates first ever polygenic risk assessment to predict breast cancer risk in women of Hispanic ancestry.

2018

Paul Diaz Named CEO

Paul J. Diaz appointed president and chief executive officer of Myriad Genetics.

2020

Helping More Patients

Myriad Genetics joins forces with Intermountain Precision Genomics for a comprehensive offering of germline and somatic tumor testing services.

2021

Expanding Access to Genetic Testing

Myriad Genetics launches the first polygenic breast cancer risk assessment score (RiskScore®) validated for women of all ancestries.

2021

Launch of Precise™ Solutions

Myriad Genetics advances precision oncology with new Precise Solutions, combining genetic insights from multiple tests to guide treatment decisions and improve patient care.

2022

Join Us in Celebrating Genetic Counselors